巴戟天丸对去势大鼠骨组织RANK、NFAT2和V-ATPmRNA的影响
|
摘要
目的探讨巴戟天丸对去势大鼠骨组织细胞核因子κB受体活化因子(RANK),活化T细胞核因子信号通路(NFAT) 2和空泡型V-ATP酶(V-ATPmRNA)表达的影响。方法 48只SD大鼠随机分为假手术组(SHAM组),去势组(OVX组),去势+巴戟天丸治疗组(OVX+巴戟天丸组),每组16只。巴戟天丸灌胃干预9周或18周后检测各组大鼠骨密度和骨组织RANK、NFAT2和V-ATP的mRNA表达水平。结果 OVX组BMD在第9周(P <0. 05)和第18周均低于SHAM组(P <0. 01)。干预18周后,OVX+巴戟天丸组骨密度(BMD)高于OVX组(P <0. 05),且OVX+巴戟天丸组骨组织RANK、NFAT2和V-ATP mRNA表达也下降(P <0. 05,P <0. 01,P <0. 05)。结论巴戟天丸可改善去势大鼠骨密度且下调其骨组织中RANK、NFAT2和V-ATPmRNA的表达,从而达到抑制破骨细胞活性和延缓去势大鼠的骨吸收。
Objective To investigate the effect of Morinda officinalis Pill on the mRNA expression of RANK、NFAT2 and V-ATP in the bone of ovariectomized rats. Methods Forty eight Sprague-Dawley rats were randomly divided into SHAM group,OVX group and OVX + Morinda officinalis Pill group. The levels of Bone mineral density( BMD) and mRNA expression of RANK、NFAT2 and V-ATP in bone were detected at 9 thand 18 thweeks after intervention. Results Compared to SHAM group,the BMD was decreased gradually in OVX group( P < 0. 05). BMD of OVX + Morinda officinalis Pill group was higher than that of OVX group after 18 thweeks intervention( P < 0. 05). Meanwhile,the expression of RANK、NFAT2 and V-ATP mRNA in OVX + Morinda officinalis Pill group were lower than that in OVX group( P <0. 05,P < 0. 01). Conclusion Morinda officinalis Pill can reduce the bone resorption of osteoclasts by down-regulating the mRNA expression of RANK、NFAT2 and V-ATP in ovariectomized rats,and then delay bone loss in ovariectomized rats.
Objective To investigate the effect of Morinda officinalis Pill on the mRNA expression of RANK、NFAT2 and V-ATP in the bone of ovariectomized rats. Methods Forty eight Sprague-Dawley rats were randomly divided into SHAM group,OVX group and OVX + Morinda officinalis Pill group. The levels of Bone mineral density( BMD) and mRNA expression of RANK、NFAT2 and V-ATP in bone were detected at 9 thand 18 thweeks after intervention. Results Compared to SHAM group,the BMD was decreased gradually in OVX group( P < 0. 05). BMD of OVX + Morinda officinalis Pill group was higher than that of OVX group after 18 thweeks intervention( P < 0. 05). Meanwhile,the expression of RANK、NFAT2 and V-ATP mRNA in OVX + Morinda officinalis Pill group were lower than that in OVX group( P <0. 05,P < 0. 01). Conclusion Morinda officinalis Pill can reduce the bone resorption of osteoclasts by down-regulating the mRNA expression of RANK、NFAT2 and V-ATP in ovariectomized rats,and then delay bone loss in ovariectomized rats.
引文
[1]Schurman L,Galich AM,González C,et al. Argentine guidelines for the diagnosis,prevention and treatment of osteoporosis,2015[J]. Medicina(B Aires),2017,77(1):46-60.
[2]Chen Peng,Li Zhanzhan,Hu Yihe. Prevalence of osteoporosis in China:a meta-analysis and systematic review[J]. BMC Public Health,2016(16):1039.
[3]Kajiya H. Calcium signaling in osteoclast differentiation and bone resorption[J]. Adv Exp Med Biol,2012(740):917-932.
[4]Liu W,Zhang X. Receptor activator of nuclear factor-κB ligand(RANKL)/RANK/osteoprotegerin system in bone and other tissues(review)[J]. Mol Med Rep,2015,11(5):3212-3218.
[5]Zhang Y,Jiang P,Li W,et al. Calcineurin/NFAT signaling pathway mediates titanium particleinduced inflammation and osteoclast formation by inhibiting RANKL and MCSF in vitro[J]. Mol Med Rep,2017,16(6):8223-8230.
[6]Qin A,Cheng TS,Pavlos NJ,et al. V-ATPases in osteoclasts:structure,function and potential inhibitors of bone resorption[J]. Int J Biochem Cell Biol,2012(44):1422-1435.
[7]Livak KJ,Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2-ΔΔCtmethod[J]. J Methods,2001(25):402-408.
[8]葛继荣,郑洪新,万小明,等.中医药防治原发性骨质疏松症专家共识(2015)[J].中国骨质疏松杂志,2015(9):1023-1028.
[9]中华医学会骨质疏松和骨矿盐疾病分会.原发性骨质疏松症诊疗指南(2017)[J].中华骨质疏松和骨矿盐疾病杂志,2017,10(5):411-412.
[10]赵佶.圣济总录[M].北京:人民出版社,2011:973.
[11]凌昆,赵诣,郭素华.巴戟天药物血清对成骨细胞生物学特性的影响[J].中华中医药杂志,2010,25(6):846-849.
[12]何剑全,陈健.巴戟天抗骨质疏松症作用机理实验研究进展[J].世界中西医结合杂志,2010,5(6):546-548.
[13]邵航,张俐.补骨脂抗骨质疏松作用的研究进展[J].中国中医骨伤科杂志,2015,(23)3:69-71.
[14]Niu C,Xiao F,Yuan K,et al. Nardosinone Suppresses RANKL-Induced Osteoclastogenesis and Attenuates Lipopolysaccharide-Induced Alveolar Bone Resorption[J]. Front Pharmacol,2017,12(8):626.
[15]Di Nisio C,Zizzari VL,Zara S,et al. RANK/RANKL/OPG signaling pathways in necrotic jaw bone from bisphosphonate-treated subjects[J]. Eur J Histochem,2015,59(1):2455.
[16]Cotter K,Stransky L,Mc Guire C,et al. Recent Insights into the Structure,Regulation,and? Function? of the V-ATPases[J].Trends Bisochem Sci,2015,40(10):611-622.
[2]Chen Peng,Li Zhanzhan,Hu Yihe. Prevalence of osteoporosis in China:a meta-analysis and systematic review[J]. BMC Public Health,2016(16):1039.
[3]Kajiya H. Calcium signaling in osteoclast differentiation and bone resorption[J]. Adv Exp Med Biol,2012(740):917-932.
[4]Liu W,Zhang X. Receptor activator of nuclear factor-κB ligand(RANKL)/RANK/osteoprotegerin system in bone and other tissues(review)[J]. Mol Med Rep,2015,11(5):3212-3218.
[5]Zhang Y,Jiang P,Li W,et al. Calcineurin/NFAT signaling pathway mediates titanium particleinduced inflammation and osteoclast formation by inhibiting RANKL and MCSF in vitro[J]. Mol Med Rep,2017,16(6):8223-8230.
[6]Qin A,Cheng TS,Pavlos NJ,et al. V-ATPases in osteoclasts:structure,function and potential inhibitors of bone resorption[J]. Int J Biochem Cell Biol,2012(44):1422-1435.
[7]Livak KJ,Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2-ΔΔCtmethod[J]. J Methods,2001(25):402-408.
[8]葛继荣,郑洪新,万小明,等.中医药防治原发性骨质疏松症专家共识(2015)[J].中国骨质疏松杂志,2015(9):1023-1028.
[9]中华医学会骨质疏松和骨矿盐疾病分会.原发性骨质疏松症诊疗指南(2017)[J].中华骨质疏松和骨矿盐疾病杂志,2017,10(5):411-412.
[10]赵佶.圣济总录[M].北京:人民出版社,2011:973.
[11]凌昆,赵诣,郭素华.巴戟天药物血清对成骨细胞生物学特性的影响[J].中华中医药杂志,2010,25(6):846-849.
[12]何剑全,陈健.巴戟天抗骨质疏松症作用机理实验研究进展[J].世界中西医结合杂志,2010,5(6):546-548.
[13]邵航,张俐.补骨脂抗骨质疏松作用的研究进展[J].中国中医骨伤科杂志,2015,(23)3:69-71.
[14]Niu C,Xiao F,Yuan K,et al. Nardosinone Suppresses RANKL-Induced Osteoclastogenesis and Attenuates Lipopolysaccharide-Induced Alveolar Bone Resorption[J]. Front Pharmacol,2017,12(8):626.
[15]Di Nisio C,Zizzari VL,Zara S,et al. RANK/RANKL/OPG signaling pathways in necrotic jaw bone from bisphosphonate-treated subjects[J]. Eur J Histochem,2015,59(1):2455.
[16]Cotter K,Stransky L,Mc Guire C,et al. Recent Insights into the Structure,Regulation,and? Function? of the V-ATPases[J].Trends Bisochem Sci,2015,40(10):611-622.